Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Callea · SciRah

Researcher profile · Semantic Scholar

V. Callea

Share profile

V. Callea — researcher profile on SciRah

h-index: 40
Works: 194
Citations: 7,854

Most-cited papers

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
A. Palumbo, S. Bringhen, T. Caravita, E. Merla +18 more
2006The Lancet822 citations
Semantic Scholar
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
A. Palumbo, S. Bringhen, D. Rossi, Maide Cavalli +20 more
2010Journal of Clinical Oncology411 citations Open access
Semantic Scholar
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
S. Bringhen, A. Larocca, D. Rossi, Maide Cavalli +21 more
2010Blood389 citations Open access
Semantic Scholar
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
A. Palumbo, S. Bringhen, A. Liberati, T. Caravita +16 more
2008Blood382 citations Open access
Semantic Scholar
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
A. Palumbo, M. Cavo, S. Bringhen, E. Zamagni +28 more
2011Journal of Clinical Oncology319 citations Open access
Semantic Scholar
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
M. Cavo, L. Pantani, M. Petrucci, F. Patriarca +26 more
2012Blood311 citations Open access
Semantic Scholar
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
M. Ladetto, G. Pagliano, S. Ferrero, F. Cavallo +16 more
2010Journal of Clinical Oncology278 citations
Semantic Scholar
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.
M. Ladetto, F. de Marco, F. Benedetti, U. Vitolo +22 more
2008Blood253 citations
Semantic Scholar
Splenic marginal zone lymphoma: a prognostic model for clinical use.
L. Arcaini, M. Lazzarino, N. Colombo, S. Burcheri +23 more
2006Blood250 citations Open access
Semantic Scholar
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
S. Bringhen, M. Mateos, S. Zweegman, A. Larocca +24 more
2013Haematologica213 citations Open access
Semantic Scholar
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
A. Palumbo, M. T. Ambrosini, G. Benevolo, P. Pregno +11 more
2007Blood174 citations Open access
Semantic Scholar
Chlorambucil plus rituximab with or without maintenance rituximab as first‐line treatment for elderly chronic lymphocytic leukemia patients
R. Foà, I. Del Giudice, A. Cuneo, G. del Poeta +36 more
2014American journal of hematology/oncology123 citations Open access
Semantic Scholar
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.
A. Palumbo, F. Gay, S. Bringhen, A. Falcone +11 more
2008Annals of Oncology120 citations Open access
Semantic Scholar
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.
A. Palumbo, S. Bringhen, B. Bruno, A. Falcone +21 more
2010Blood93 citations Open access
Semantic Scholar
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival
S. Ferrero, M. Ladetto, D. Drandi, F. Cavallo +21 more
2014Leukemia89 citations Open access
Semantic Scholar
Safety and efficacy of bortezomib‐based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA
F. Morabito, M. Gentile, S. Ciolli, M. T. Petrucci +18 more
2010European Journal of Haematology83 citations Open access
Semantic Scholar
Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).
M. Cavo, F. Patriarca, P. Tacchetti, M. Galli +20 more
200774 citations
Semantic Scholar
Molecular and transcriptional characterization of 17p loss in B‐cell chronic lymphocytic leukemia
S. Fabris, L. Mosca, K. Todoerti, G. Cutrona +14 more
2008Genes, Chromosomes and Cancer73 citations Open access
Semantic Scholar
Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion
L. Mosca, S. Fabris, M. Lionetti, K. Todoerti +15 more
2010Clinical Cancer Research69 citations Open access
Semantic Scholar
Circulating miRNA markers show promise as new prognosticators for multiple myeloma
A. Rocci, C. Hofmeister, S. Geyer, Andrew Stiff +28 more
2014Leukemia60 citations Open access
Semantic Scholar
Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia
F. Morabito, G. Cutrona, M. Gentile, S. Matis +16 more
2009British Journal of Haematology60 citations Open access
Semantic Scholar
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience
L. Laurenti, M. Tarnani, I. Nichele, S. Ciolli +16 more
2011American journal of hematology/oncology54 citations
Semantic Scholar
A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients
A. Palumbo, S. Bringhen, D. Rossi, V. Magarotto +15 more
200854 citations
Semantic Scholar
Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells
G. Cutrona, M. Colombo, S. Matis, M. Fabbi +8 more
2008Haematologica49 citations Open access
Semantic Scholar
The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience
S. Molica, F. Mauro, V. Callea, D. Giannarelli +5 more
2010Haematologica44 citations Open access
Semantic Scholar
Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients.
A. Palumbo, S. Bringhen, D. Rossi, R. Ria +26 more
200940 citations
Semantic Scholar
Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy
V. Callea, M. Brugiatelli, C. Stelitano, M. Gentile +2 more
2006Leukemia and Lymphoma35 citations
Semantic Scholar
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
Ilaria Saltarella, F. Morabito, N. Giuliani, C. Terragna +25 more
2019Journal of Hematology & Oncology34 citations Open access
Semantic Scholar
B‐cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia
Francesco Maura, C. Visco, Erika Falisi, G. Reda +18 more
2012American journal of hematology/oncology34 citations Open access
Semantic Scholar
IgV gene intraclonal diversification and clonal evolution in B‐cell chronic lymphocytic leukaemia
D. Bagnara, V. Callea, C. Stelitano, F. Morabito +7 more
2006British Journal of Haematology27 citations
Semantic Scholar
A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis
R. Foà, S. Ciolli, F. Di Raimondo, G. del Poeta +28 more
201025 citations
Semantic Scholar
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
F. Morabito, C. Stelitano, S. Luminari, C. Mammi' +10 more
2006Bone Marrow Transplantation25 citations Open access
Semantic Scholar
Prognostic relevance of in vitro response to cell stimulation via surface IgD in binet stage a CLL
F. Morabito, G. Cutrona, M. Gentile, M. Fabbi +14 more
2010British Journal of Haematology23 citations
Semantic Scholar
Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors
A. Palumbo, S. Bringhen, Maide Cavalli, R. Ria +21 more
201022 citations
Semantic Scholar
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial
M. Ladetto, Sonia Vallet, F. Benedetti, U. Vitolo +16 more
2006Leukemia22 citations
Semantic Scholar
Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma
E. Iannitto, V. Minardi, V. Callea, C. Stelitano +9 more
2006European Journal of Haematology19 citations
Semantic Scholar
An Italian retrospective study on the routine clinical use of low‐dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients
A. Cortelezzi, G. Gritti, L. Laurenti, A. Cuneo +13 more
2012British Journal of Haematology18 citations Open access
Semantic Scholar
Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative Analysis
C. Terragna, E. Zamagni, M. Petrucci, S. Durante +18 more
201016 citations
Semantic Scholar
Proposal and Validation of Prognostic Scoring Systems for IgG and IgA Monoclonal Gammopathies of Undetermined Significance
F. Rossi, M. Petrucci, A. Guffanti, L. Marcheselli +13 more
2009Clinical Cancer Research15 citations
Semantic Scholar
Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment
R. Foà, S. Ciolli, F. Di Raimondo, G. del Poeta +30 more
201114 citations
Semantic Scholar
Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Trasplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study
M. Ladetto, G. Pagliano, S. Ferrero, F. Cavallo +14 more
200814 citations
Semantic Scholar
Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients
M. Martino, G. Console, V. Callea, C. Stelitano +5 more
2007European Journal of Haematology14 citations
Semantic Scholar
Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study
M. Cavo, G. Perrone, S. Buttignol, E. Calabrese +21 more
201012 citations
Semantic Scholar
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL
M. Ladetto, S. Ferrero, D. Drandi, F. Cavallo +18 more
201111 citations
Semantic Scholar
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
E. Iannitto, V. Minardi, P. Gobbi, G. Calvaruso +16 more
2009Clinical Lymphoma & Myeloma10 citations Open access
Semantic Scholar
Bortezomib, Melphalan, Prednisone and Thalidomide (Vmpt)versus Bortezomib, Melphalan and Prednisone (Vmp) Inelderly Newly Diagnosed Myeloma Patients: A Prospective,randomized, Phase Iii Study
Andrea Palumbo, S. Bringhen, D. Rossi, R. Ria +26 more
20099 citations
Semantic Scholar
A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens.
A. Palumbo, M. Cavo, S. Bringhen, G. Perrone +16 more
20079 citations
Semantic Scholar
High‐dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients
M. Martino, G. Console, G. Irrera, G. Praticò +8 more
2006American journal of hematology/oncology9 citations Open access
Semantic Scholar
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens
E. Sabattini, Rocio Orduz, C. Campidelli, P. Zinzani +6 more
2006Journal of Clinical Pathology8 citations Open access
Semantic Scholar
Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.
M. Ladetto, G. Pagliano, S. Ferrero, F. Cavallo +19 more
20096 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Boccadoro×25
Invite
M. Boccadoro — researcher profile on SciRah
A. Palumbo×22
Invite
A. Palumbo — researcher profile on SciRah
F. Morabito×22
Invite
F. Morabito — researcher profile on SciRah
S. Bringhen×20
Invite
S. Bringhen — researcher profile on SciRah

×18

Invite

P. Musto — researcher profile on SciRah

T. Caravita×13

Invite

T. Caravita — researcher profile on SciRah

Invite

M. Grasso — researcher profile on SciRah

M. Petrucci×12

Invite

M. Petrucci — researcher profile on SciRah

Invite

R. Ria — researcher profile on SciRah

F. Patriarca×12

Invite

F. Patriarca — researcher profile on SciRah

Invite

A. Falcone — researcher profile on SciRah

Invite

D. Rossi — researcher profile on SciRah